Antifungal activity of ETD151 against azole-susceptible and -resistant Aspergillus fumigatus clinical isolates
Open Access
- 10 October 2025
- journal article
- Published by Elsevier in Current Research in Microbial Sciences
- Vol. 9, 100486
Abstract
No abstract availableKeywords
Funding Information
- Association Vaincre la Mucoviscidose (RF20230503260)
- Association Vaincre la Mucoviscidose (RF20240503525)
- Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
This publication has 64 references indexed in Scilit:
- Beyond bacteria: the growing threat of antifungal resistanceThe Lancet, 2024
- Lactoferrin as a potential therapeutic for the treatment of Candida-associated denture stomatitisJournal of Oral Biosciences, 2024
- Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectivesEuropean Journal of Medicinal Chemistry, 2021
- The antifungal arsenal: alternative drugs and future targetsInternational Journal of Antimicrobial Agents, 2018
- Antimicrobial Peptides: An Introduction2016
- The Aspergillus nidulans acuL gene encodes a mitochondrial carrier required for the utilization of carbon sources that are metabolized via the TCA cycleFungal Genetics and Biology, 2014
- Induced Resistance to the Designer Proline-rich Antimicrobial Peptide A3-APO does not Involve Changes in the Intracellular Target DnaKInternational Journal of Peptide Research and Therapeutics, 2009
- The Aspergillus nidulans cetA and calA genes are involved in conidial germination and cell wall morphogenesisFungal Genetics and Biology, 2008
- Cationic peptides: effectors in innate immunity and novel antimicrobialsThe Lancet Infectious Diseases, 2001
- Human β-Defensin-1 Is a Salt-Sensitive Antibiotic in Lung That Is Inactivated in Cystic FibrosisCell, 1997